Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Potential involvement of type II phospholipase A2 in atherosclerosis.

× No keyword cloud information.

9 in total

1. Role of sphingomyelin and ceramide in the regulation of the activity and fatty acid specificity of group V secretory phospholipase A2.

Authors: Dev K Singh; Laurence R Gesquiere; Papasani V Subbaiah
Journal: Arch Biochem Biophys Date: 2006-11-21 Impact factor: 4.013

2. Stimulatory and inhibitory actions of lysophosphatidylcholine, depending on its fatty acid residue, on the phospholipase C/Ca2+ system in HL-60 leukaemia cells.

Authors: F Okajima; K Sato; H Tomura; A Kuwabara; H Nochi; K Tamoto; Y Kondo; Y Tokumitsu; M Ui
Journal: Biochem J Date: 1998-12-01 Impact factor: 3.857

3. Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein.

Authors: Sanna Taskinen; Petri T Kovanen; Hanna Jarva; Seppo Meri; Markku O Pentikäinen
Journal: Biochem J Date: 2002-10-15 Impact factor: 3.857

Review 4. Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes.

Authors: Robert S Rosenson; Michael H Gelb
Journal: Curr Cardiol Rep Date: 2009-11 Impact factor: 2.931

Review 5. Role of secretory phospholipases in atherogenesis.

Authors: Ann-Cathrine Jönsson-Rylander; Sofia Lundin; Birgitta Rosengren; Camilla Pettersson; Eva Hurt-Camejo
Journal: Curr Atheroscler Rep Date: 2008-06 Impact factor: 5.113

6. AMPK Signaling Involvement for the Repression of the IL-1β-Induced Group IIA Secretory Phospholipase A2 Expression in VSMCs.

Authors: Khadija El Hadri; Chantal Denoyelle; Lucas Ravaux; Benoit Viollet; Marc Foretz; Bertrand Friguet; Mustapha Rouis; Michel Raymondjean
Journal: PLoS One Date: 2015-07-10 Impact factor: 3.240

Potential involvement of type II phospholipase A2 in atherosclerosis.

1. Role of sphingomyelin and ceramide in the regulation of the activity and fatty acid specificity of group V secretory phospholipase A2.

2. Stimulatory and inhibitory actions of lysophosphatidylcholine, depending on its fatty acid residue, on the phospholipase C/Ca2+ system in HL-60 leukaemia cells.

3. Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein.

Review 4. Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes.

Review 5. Role of secretory phospholipases in atherogenesis.

6. AMPK Signaling Involvement for the Repression of the IL-1β-Induced Group IIA Secretory Phospholipase A2 Expression in VSMCs.

7. A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs.

8. Platelet-activating factor acetylhydrolase and transacetylase activities in human aorta and mammary artery.

Review 9. Biology of secretory phospholipase A2.